Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 Phase II in Non-small Cell Lung Cancer
CTR20190195Phase 2Terminated
- Sponsor
- Alphamab Oncology
- Start
- Jan 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in non-small cell lung cancer (NSCLC), sponsored by Alphamab Oncology. Started Jan 2019; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190195.